Quality by digital design for accelerated sustainable nanomedicine development

Drug delivery systems, diagnostics, and treatments are all being revolutionized by nanomedicine, greatly improving contemporary healthcare. However, traditional nanomedicine development relies on extensive experimental testing, which is costly, time-consuming, and environmentally harmful. To address these challenges, the Quality by Digital Design (QbDD) concept and framework have been developed, integrating digital technologies such as substantial data analytics, Artificial Intelligence (AI), Machine Learning (ML), and computational modeling to transform nanoparticle design. QbDD enables smart digital simulations and predictive analytics to improve nanoparticles with precise bio-physicochemical properties, thereby enhancing batch reproducibility while reducing reliance on resource-intensive physical experiments, lowering costs, and minimizing environmental impact. This digital infrastructure not only optimizes nanoparticle design and efficacy but also ensures compliance with regulatory standards. This review examines the fundamentals of nano-informatics and its integration with QbDD in nanomedicine, focusing on AI-powered molecular simulations and in silico screening to pre-select nanoparticle candidates, thereby reducing dependence on labor-intensive experimental validation. Furthermore, it discusses digital innovations in nanopharmaceuticals, including real-time monitoring systems and digital twins for process verification, highlighting how these advancements enhance nanoparticle synthesis, making it more efficient, cost-effective, and sustainable.